Anti-EGFR/c-Met Bispecific Antibody CKD-702

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A tetravalent, bispecific antibody composed of a single-chain variable fragment (scFv) targeting epidermal growth factor receptor (EGFR) fused to the c-terminus of an immunoglobulin G1 (IgG1) antibody targeting hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody CKD-702 simultaneously targets and binds to the extracellular domains of wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and c-Met-mediated signaling, thereby inhibiting tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.

**Synonyms:** - Anti-EGFR/Anti-c-Met Bispecific Antibody CKD-702 - CKD 702 - CKD-702 - CKD702 - EGFR x c-Met Bispecific Antibody CKD-702